Exportació completada — 
Loading...

The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia

The safety and efficacy of ibrutinib, an oral inhibitor of Bruton tyrosine kinase, were evaluated with chemoimmunotherapy (CIT) in a multicenter phase 1b study. Patients with relapsed/refractory chronic lymphocytic leukemia received bendamustine and rituximab (BR) or fludarabine, cyclophosphamide, a...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Blood
Main Authors: Brown, Jennifer R., Barrientos, Jacqueline C., Barr, Paul M., Flinn, Ian W., Burger, Jan A., Tran, Anh, Clow, Fong, James, Danelle F., Graef, Thorsten, Friedberg, Jonathan W., Rai, Kanti, O’Brien, Susan
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Hematology 2015
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4424415/
https://ncbi.nlm.nih.gov/pubmed/25755291
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-09-585869
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!